SWISS_EVIDENCE - Compartment Compressibility Monitoring Using CPM#1

Compartment Syndromes Clinical Trial

Official title:

Clinical Validation of CPM#1 Compression Ratio Measurement on Healthy Volunteers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05367921
• Other study ID #: SWISS_EVIDENCE
• Status: Completed
• Phase: N/A
• Start date: May 4, 2022
• Est. completion date: May 17, 2022

Study information

• Verified date: May 2022
• Source: Compremium AG
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Compartment syndrome is a very serious musculoskeletal disorder, which can lead to potentially devastating consequences, such as limb amputation and life-threatening conditions. It is a well described medical condition considered to be an orthopaedic emergency affecting all ages. Even though compartment syndrome is a well described medical condition, the appropriate treatment (i.e., fasciotomy to release tissue pressure) is invasive and involves its own risks. Furthermore, and of most critical importance is the timing for the intervention of a fasciotomy. The concerned limb may already have had severe, sometimes even irreversible, tissue damage due to high intra-compartmental pressure within 6 to 10 hours. The standard diagnostic method for compartment syndrome is an invasive intra-compartmental pressure measurement via insertion of a pressure monitoring device into the muscle compartment. Commercially available intra compartmental pressure monitors have a highly variable intra-observer reproducibility and user errors are common. Compared to the invasive modalities, the Compremium Compartmental Compressibility Monitoring System (CPM#1) shows promising advantages for the clinical application. Not only is the technology used for the CPM#1 device safe and non-invasive for the patient with minimal training required for the healthcare professionals, but it has also demonstrated high intra- and inter-observer reproducibility (as per bench tests and clinical settings with prototypes, to be confirmed in clinical studies like this one). The use of the CPM#1 device therefore facilitates the measurements, as it is based on pre-existing ultrasound methods and avoids any further risks to the patients compared to invasive compartmental pressure diagnosis methods.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 21
• Est. completion date: May 17, 2022
• Est. primary completion date: May 17, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 84 Years

Eligibility

Inclusion Criteria:

• Healthy volunteers
• Male and female
• Age between 18 and 84

Exclusion Criteria:

• Previous surgery to or fracture of the lower leg
• Peripheral arterial or venous disease
• History of compartment syndrome
• Limb anomalies
• General muscle disorder
• Participants under the influence of excessive alcohol, consumption of narcotics or benzodiazepines prior to procedure
• Participants under the effect of analgesic (< 12 hours)

Related Conditions & MeSH terms

• Compartment Syndromes

Intervention

Device:
• Measurement of compartment compressibility
Application of the CPM#1 device for compartment compressibility ratio measurement - 4 measurements on both legs of each healthy volunteer will be performed

Locations

Country	Name	City	State
Switzerland	Universitätsklinik für Orthopädische Chirurgie und Traumatologie Inselspital	Bern

Sponsors (1)

Lead Sponsor	Collaborator
Compremium AG

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Assessment of adverse events	Safety of the procedure will be assessed by documenting adverse events (description of the adverse events, number of participants).	During the procedure which should last about 10 min/patient
Other	Assessment of device deficiencies	Safety of the procedure will be assessed by documenting device deficiencies (description)	During the procedure which should last about 10 min/patient
Other	New risk identification	Practitioner will be asked to identify risk due to the application of the device in patient care.	Within 12 hours after procedure (no follow up is planned)
Primary	Inter-operator reproducibility with 3 raters	Inter-operator reproducibility will be assessed using intra-class correlation coefficients (two-way random effects, single rater, absolute agreement). Three independent raters will conduct one measurement on each of both legs of 21 volunteers.	During the procedure which should last about 10 min/patient
Secondary	Intra-operator reproducibility	Intra-operator reproducibility will be assessed using intra-class correlation coefficients (two-way mixed effects, single measurement, absolute agreement). One of the three independent raters will conduct two measurements on 42 legs (21 volunteers).	During the procedure which should last about 10 min/patient
Secondary	Participant's reported pain: baseline	Participant's reported pain will be assessed using a 0-100mm Visual Analogue Scale (VAS) at specific time points.	Before (5 min before procedure).
Secondary	Participant's reported pain: at highest externally applied pressure	Participant's reported pain will be assessed using a 0-100mm Visual Analogue Scale (VAS) at specific time points.	During the procedure (the procedure will last about 10 min/patient)
Secondary	Participant's reported pain: after the procedure	Participant's reported pain will be assessed using a 0-100mm Visual Analogue Scale (VAS) at specific time points.	Immediately after procedure (no follow up is planned)